Fort Lauderdale, FL – According to filings with the U.S. Securities and Exchange Commission, Syncromune is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Eamonn Hobbs played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Syncromune
syncromune is a clinical stage biopharmaceutical company developing a new #cancer therapy that optimizes intratumoral #immunotherapy and synchronizes immune functions to kill metastatic solid tumors.

To learn more about Syncromune, visit http://syncromune.com/

Contact:
Eamonn Hobbs, Chief Executive Officer
518-796-6110

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved